March 9, 2022
Nippon Chemiphar is acquiring exclusive commercialization rights in Japan for another cancer drug being developed by Tokushima-based biotech Delta-Fly Pharma, DFP-14323, the two companies said on March 8. Under their agreement, Delta-Fly will receive an upfront payment of 200 million...read more